This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Richard L. Landau, MD

JAMA. 1984;251(13):1747-1748.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The story of the development of antithyroid drugs, which reached its climax with the publication of "Treatment of Hyperthyroidism With Thiourea and Thiouracil,"¹ is an early example of the sort of research that has transformed clinical science into the most explosive branch of biology. As far as one can tell from the published literature, Astwood, a reproductive endocrinologist, had not directed his research efforts to the control of the thyroid before publication of the articles to be mentioned. One must assume, however, that as a clinician, he dealt with hyperthyroidism and longed for a more effective way of managing the disease. It must have been so, for when he became aware of several available, relatively safe chemical goitrogens, he certainly grasped their potential clinical importance and ran.

First Goitrogens

In 1941, Julia and C. G. MacKenzie and E. V. McCollum,² from the School of Hygiene and Public Health . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Medicine, Section of Endocrinology, University of Chicago.

Footnotes
Reprint requests to Department of Medicine, University of Chicago, 5841 S Maryland St, Chicago, IL 60637 (Dr Landau).

A commentary on Astwood EB: Treatment of hyperthyroidism with thiourea and thiouracil. JAMA 1943;122:78-81.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?